P. Pierotti

发表

Human alpha defensin in HIV-exposed but uninfected individuals.

M. Clerici, M. Biasin, F. Mazzotta, 2004, Journal of acquired immune deficiency syndromes.

Mycobacterium yongonense in Pulmonary Disease, Italy

G. Rossolini, E. Tortoli, P. Pierotti, 2013, Emerging infectious diseases.

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia

A. d’Arminio Monforte, M. Massari, M. Pistello, 2021, JAMA network open.

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

C. Tinelli, L. Minoli, C. Torti, 2005, The Journal of antimicrobial chemotherapy.

Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.

S. Di Giambenedetto, C. Torti, N. Manca, 2007, AIDS patient care and STDs.

Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients.

A. De Luca, C. Torti, G. Carosi, 2004, AIDS patient care and STDs.

[Appendicitis: microbial interactions and new pathogens].

S. Corradini, A. Belli, P. Pierotti, 1992, Recenti progressi in medicina.

TLR Activation Pathways in HIV-1–Exposed Seronegative Individuals

M. Clerici, M. Biasin, S. Lo Caputo, 2010, The Journal of Immunology.

TLR Activation Pathways in HIV-1

M. Clerici, M. Biasin, F. Mazzotta, 2010 .

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

S. Leone, S. Lo Caputo, F. Mazzotta, 2015, International journal of epidemiology.

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

R. Maserati, A. de Silvestri, A. Antinori, 2007, The Journal of antimicrobial chemotherapy.

90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection.

S. Iacobelli, G. Antonelli, F. Dianzani, 1993, Journal of acquired immune deficiency syndromes.

Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.

C. Tinelli, R. Maserati, A. Lazzarin, 2003, Journal of acquired immune deficiency syndromes.

HBV whole-genome mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study

M. Rapicetta, F. Mazzotta, D. Genovese, 2014, Infection.

Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors.

M. Zazzi, F. Mazzotta, G. Venturi, 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

HIV‐1 subtypes and circulating recombinant forms (CRFs) from HIV‐infected patients residing in two regions of central and southern Italy

F. Mazzotta, C. Balotta, C. Riva, 2005, Journal of medical virology.

Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)

D. Francisci, F. Vichi, P. Pierotti, 2021, Journal of Infection.

HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.

C. Tinelli, S. Lo Caputo, F. Mazzotta, 2004, Journal of acquired immune deficiency syndromes.

Human (cid:1) Defensin in HIV-Exposed But Uninfected Individuals

M. Clerici, M. Biasin, F. Mazzotta, 2018 .

Human &agr; Defensin in HIV-Exposed But Uninfected Individuals

M. Clerici, M. Biasin, F. Mazzotta, 2004 .

Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients

M. Clerici, F. Mazzotta, M. Saresella, 2005, AIDS.

Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study

F. Donato, M. Fabbiani, E. Raffetti, 2015, BMC Public Health.

Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

C. Tinelli, C. Boucher, S. Lo Caputo, 2003, The Journal of infectious diseases.

Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin.

F. Mazzotta, P. Blanc, P. Pierotti, 2003, Journal of biological regulators and homeostatic agents.

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.

C. Tinelli, A. De Luca, C. Torti, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.